8-K: Glucotrack Bolsters Clinical Team with Cardiology MD

Glucotrack, Inc. announced the appointment of David S. Hirsh, MD, as Medical Director, Cardiology, to advance its continuous blood glucose monitor through clinical milestones.

Summary

• Glucotrack, Inc. appointed David S. Hirsh, MD, as Medical Director, Cardiology, to its clinical advisory team.
• Dr. Hirsh will provide strategic leadership for clinical and educational initiatives related to the Company's Continuous Blood Glucose Monitor (CBGM).
• His expertise in interventional cardiology directly supports the CBGM's unique intravascular placement, which builds on proven cardiovascular design concepts.
• Dr. Hirsh's oversight will be valuable for site selection, physician education, and protocol compliance for ongoing clinical trials, including an OUS early feasibility study and an upcoming US pilot study.
• The Glucotrack CBGM is a long-term implantable system designed for up to three years of continuous, accurate blood glucose monitoring without a wearable component.
• Unlike traditional CGMs, Glucotrack's CBGM measures glucose directly from blood, aiming to provide real-time readings without lag time.

Sentiment

Score: 8

Explanation: The announcement of a highly qualified medical director joining the team is a strong positive, indicating progress in clinical development and strengthening the Company's expertise for its innovative product. This strategic hire de-risks the clinical pathway for a potentially disruptive technology.

Positives

• Appointment of David S. Hirsh, MD, an experienced cardiac electrophysiologist, strengthens the clinical leadership team.
• Dr. Hirsh's expertise directly supports the CBGM's unique intravascular placement, leveraging established cardiovascular procedures.
• The CBGM offers a long-term (up to three years) implantable solution, eliminating the need for a wearable component.
• The CBGM measures glucose directly from blood, aiming for real-time accuracy without the lag associated with interstitial fluid measurements.
• The Company is progressing through critical clinical milestones, including an OUS early feasibility study and an upcoming US pilot study.

Risks

• Ability to raise additional capital to finance operations (through equity offerings, debt financings, or strategic collaborations).
• Risks related to the receipt and timing of regulatory approvals, including U.S. Food and Drug Administration (FDA) approval.
• Risks concerning the enrollment of patients in, and the conduct of, clinical trials.
• Risks related to future distribution agreements.
• Risks associated with the ability to hire and retain qualified personnel, including sales and distribution personnel.
• Additional risk factors described in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 31, 2025.

Future Outlook

The Company plans to advance its Continuous Blood Glucose Monitor (CBGM) through ongoing clinical trials, including an OUS early feasibility study and an upcoming US pilot study, with the ultimate goal of commercialization. Dr. Hirsh's role will also be critical for developing education and training programs for cardiac interventionalists and engaging with the endocrinology community for coordinated clinical care.

Management Comments

• Paul V. Goode, PhD, President and CEO of Glucotrack: "We are delighted to welcome Dr. Hirsh to the Company in this pivotal role supporting our novel clinical development program. Dr. Hirsh's expertise in interventional cardiology procedures directly supports our CBGMs unique intravascular placementan approach that builds on proven cardiovascular design concepts and outpatient procedures to deliver accurate, real-time glucose readings. As we advance through our clinical trials, including our long-term OUS early feasibility study and upcoming US pilot study, his clinical oversight will be valuable for appropriate site selection, physician education and protocol compliance."
• David S. Hirsh, MD, Medical Director, Cardiology: "I am honored to join Glucotrack during this exciting phase of clinical development. Glucotracks approach of using proven cardiovascular implantation techniques for continuous blood glucose monitoring represents a breakthrough in diabetes care and I look forward to applying my cardiology expertise to help advance this technology through clinical trials and toward commercialization."

Industry Context

This announcement positions Glucotrack as an innovator in the diabetes care market, specifically in continuous glucose monitoring. Its CBGM's direct blood glucose measurement and long-term implantable nature differentiate it from traditional continuous glucose monitoring systems that measure interstitial fluid and often require wearable components. The strategic hire of a cardiology expert underscores the Company's unique intravascular approach, bridging cardiovascular procedures with diabetes management.

Comparison to Industry Standards

• Glucotrack's CBGM measures glucose directly from blood, which is a key differentiator from traditional continuous glucose monitoring systems that measure glucose from interstitial fluid, aiming to eliminate the lag time typically associated with interstitial measurements.
• The CBGM is a long-term implantable system with no wearable component, offering a potentially more convenient and less intrusive solution compared to many existing CGM devices that require on-body sensors or frequent replacements.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strengthening of the clinical team, which is crucial for advancing the Company's core product and potentially increasing its value.
• People with diabetes: Potential for a more convenient, accurate, and less intrusive long-term glucose monitoring solution.
• Medical professionals (cardiac interventionalists, endocrinologists): Will be engaged in education, training, and coordinated clinical care related to the new technology.
• Employees: Strengthens the internal expertise and provides a clear direction for clinical development.

Next Steps

• Advance through long-term OUS early feasibility study for the CBGM.
• Initiate upcoming US pilot study for the CBGM.
• Develop education and training programs for cardiac interventionalists.
• Engage with the endocrinology community on coordinated clinical care for people living with diabetes.
• Progress towards commercialization of the CBGM.

Key Dates

Recommendation

The appointment of a highly experienced medical director in cardiology is a significant positive development for Glucotrack. This strategic hire strengthens the company's clinical development capabilities, which are critical for advancing its innovative long-term implantable CBGM through key clinical milestones and towards commercialization. For a medical device company in the development phase, such an addition de-risks the clinical pathway and enhances the likelihood of success for a potentially disruptive technology in diabetes care, making it an attractive long-term investment.

Keywords

Glucotrack, GCTK, diabetes, continuous glucose monitor, CBGM, medical device, cardiology, clinical trials, implantable, electrophysiology, glucose monitoring